ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

GRCL Gracell Biotechnologies Inc

10.25
0.00 (0.00%)
25 Jun 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Gracell Biotechnologies Inc NASDAQ:GRCL NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.00 0.00% 10.25 10.25 10.00 0 01:00:00

Gracell Biotechnologies to Report Third Quarter 2023 Financials on Monday, November 13, 2023

30/10/2023 12:30pm

GlobeNewswire Inc.


Gracell Biotechnologies (NASDAQ:GRCL)
Historical Stock Chart


From Jun 2023 to Jun 2024

Click Here for more Gracell Biotechnologies Charts.

Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that it plans to release unaudited financial results for the third quarter ended September 30, 2023 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, November 13, 2023. The management team will host a live audio webcast and conference call at 8:00 AM Eastern Time.

Conference call and webcast details:Monday, November 13, 2023 @ 8:00am ETInvestor domestic dial-in: (800) 715-9871 Investor international dial-in: +1 (646) 307-1963Conference ID: 3201224

Live webcast link: https://ir.gracellbio.com/news-events/events-and-presentations

A replay of the webcast will be available on ir.gracellbio.com shortly after the conclusion of the event for 90 days.

About GracellGracell Biotechnologies Inc. (“Gracell”) is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies for the treatment of cancers and autoimmune diseases. Leveraging its innovative FasTCAR and TruUCAR technology platforms and SMART CART™ technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost, and lack of effective CAR-T therapies for solid tumors and autoimmune diseases. The lead candidate BCMA/CD19 dual-targeting FasTCAR-T GC012F is currently being evaluated in clinical studies for the treatment of multiple myeloma, B-NHL and systemic lupus erythematosus (SLE). For more information on Gracell, please visit www.gracellbio.com. Follow @GracellBio on LinkedIn.

Media contacts
Marvin Tang
marvin.tang@gracellbio.com
Jessica Laub
jessica.laub@westwicke.com

Investor contacts
Gracie Tong
gracie.tong@gracellbio.com
Stephanie Carrington
stephanie.carrington@westwicke.com

1 Year Gracell Biotechnologies Chart

1 Year Gracell Biotechnologies Chart

1 Month Gracell Biotechnologies Chart

1 Month Gracell Biotechnologies Chart